JP2025118706A5 - - Google Patents
Info
- Publication number
- JP2025118706A5 JP2025118706A5 JP2025072923A JP2025072923A JP2025118706A5 JP 2025118706 A5 JP2025118706 A5 JP 2025118706A5 JP 2025072923 A JP2025072923 A JP 2025072923A JP 2025072923 A JP2025072923 A JP 2025072923A JP 2025118706 A5 JP2025118706 A5 JP 2025118706A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- pharmaceutical composition
- modified
- once
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962795629P | 2019-01-23 | 2019-01-23 | |
| US62/795,629 | 2019-01-23 | ||
| US201962837765P | 2019-04-24 | 2019-04-24 | |
| US62/837,765 | 2019-04-24 | ||
| US202062965032P | 2020-01-23 | 2020-01-23 | |
| JP2021543207A JP7675014B2 (ja) | 2019-01-23 | 2020-01-23 | Ｂ細胞免疫療法 |
| PCT/US2020/014836 WO2020154534A1 (en) | 2019-01-23 | 2020-01-23 | B cell immunotherapy |
| US62/965,032 | 2020-01-23 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543207A Division JP7675014B2 (ja) | 2019-01-23 | 2020-01-23 | Ｂ細胞免疫療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025118706A JP2025118706A (ja) | 2025-08-13 |
| JP2025118706A5 true JP2025118706A5 (https=) | 2026-01-06 |
Family
ID=71735798
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543207A Active JP7675014B2 (ja) | 2019-01-23 | 2020-01-23 | Ｂ細胞免疫療法 |
| JP2025072923A Pending JP2025118706A (ja) | 2019-01-23 | 2025-04-25 | Ｂ細胞免疫療法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543207A Active JP7675014B2 (ja) | 2019-01-23 | 2020-01-23 | Ｂ細胞免疫療法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220079986A1 (https=) |
| JP (2) | JP7675014B2 (https=) |
| CA (1) | CA3127623A1 (https=) |
| WO (1) | WO2020154534A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4236968A4 (en) * | 2020-10-30 | 2024-03-27 | Immusoft Corporation | Methods of administering genetically modified b cells for in vivo delivery of therapeutic agents |
| JP2024543827A (ja) * | 2021-11-11 | 2024-11-26 | ザ ジェネラル ホスピタル コーポレイション | 筋萎縮性側索硬化症のステージおよび進行を画定するための方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2555457C (en) * | 2004-02-09 | 2012-08-21 | Mitsubishi Pharma Corporation | A novel therapeutic agent for amyotrophic lateral sclerosis (als) or diseases caused by als |
| WO2006119170A2 (en) * | 2005-05-02 | 2006-11-09 | Avigen, Inc. | Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease |
| CA2722184A1 (en) * | 2008-04-25 | 2009-10-29 | Duke University | Regulatory b cells and their uses |
| EP2576772B1 (en) * | 2010-05-26 | 2018-12-12 | Deutsches Rheuma-Forschungszentrum Berlin | Antigen-presenting modified naïve b cells for immune suppression and a method for producing said modified cells |
| US20140079675A1 (en) * | 2011-04-04 | 2014-03-20 | HumaCell, Inc. | Repair of Neurodegenerative Diseases |
| US10017739B2 (en) * | 2012-09-06 | 2018-07-10 | Duke University | Methods of expanding and assessing B cells and using expanded B cells to treat disease |
-
2020
- 2020-01-23 US US17/424,985 patent/US20220079986A1/en active Pending
- 2020-01-23 JP JP2021543207A patent/JP7675014B2/ja active Active
- 2020-01-23 CA CA3127623A patent/CA3127623A1/en active Pending
- 2020-01-23 WO PCT/US2020/014836 patent/WO2020154534A1/en not_active Ceased
-
2025
- 2025-04-25 JP JP2025072923A patent/JP2025118706A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025118706A5 (https=) | ||
| Weber et al. | Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. | |
| Balkwill et al. | Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons | |
| US6875441B2 (en) | Composition for delivery of hematopoietic growth factor | |
| JP2025157552A5 (https=) | ||
| Liu et al. | The roles of Th cells in myocardial infarction | |
| KR100229974B1 (ko) | 충실성종양을 치료하기위한 인터루킨-4의 조성물 | |
| Callen | Intralesional corticosteroids | |
| DE69023635T2 (de) | Pharmazeutische zusammensetzung die zellen, welche mhc-klasse-ii-antigene exprimieren, zu zielzellen für cytotoxische t-zellen macht. | |
| Goulden et al. | Recombinant granulocyte colony‐stimulating factor in the management of toxic epidermal necrolysis | |
| Sarna et al. | A pilot study of intralymphatic interleukin-2. II. Clinical and biological effects | |
| JPH02218619A (ja) | 膀胱癌の治療方法 | |
| US4322405A (en) | Method for treating rheumatoid arthritis | |
| US5830454A (en) | Method for treating cell mediated autoimmune disorders using interleukin-9 | |
| Heinzerling et al. | Panniculitis after subcutaneous injection of interferon beta in a multiple sclerosis patient | |
| Doğanay et al. | A case of cutaneous anthrax with toxaemic shock | |
| JPWO2020154534A5 (https=) | ||
| US3105793A (en) | Injectable medicinal composition | |
| CA2043992A1 (en) | Use of cytokine-containing aerosols and the cytokine-containing aerosols | |
| JP2005529152A5 (https=) | ||
| JPWO2023280880A5 (https=) | ||
| Yaron et al. | Acute induction of joint inflammation in the rat by Poly I· Poly C | |
| Farber et al. | The natural history of mycosis fungoides | |
| JPH04500210A (ja) | 後天性免疫不全に関係した骨髄抑止の治療 | |
| JPWO2022093724A5 (https=) |